In our series, hypermethylation of the Wnt antagonists (DKK1, DKK2, SFRP1, SFRP4, SFRP5, and WIF1) were observed with a significant prevalence in mucinous and endometrioid carcinomas. This evidence concerns the gene WIF1 and endometrioid adenocarcinoma.